Agios Pharmaceuticals, Inc.
AGIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001439222
In the last 90 days, Agios Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 238 institutions reported holding it in 13F filings for Q2 2026, worth $2.45B in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Agios Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 160 | 1 | 165 | +6 |
| Shares | 59.5M | 58.2K | 58.9M | −540.6K (−0.9%) |
| Value | $1.67B | $1.64M | $1.36B | −$310.9M (−18.7%) |
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Agios Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nordea Investment Management AB | 306,443 | $7.08M | 0.01% |
| Integral Health Asset Management, LLC | 213,000 | $4.89M | 1.02% |
| Millennium Management LLC | 61,689 | $1.42M | 0.00% |
| UBS Oconnor LLC | 52,500 | $1.21M | 0.03% |
| Profund Advisors LLC | 38,524 | $884.9K | 0.05% |
| Martingale Asset Management L P | 26,079 | $599.0K | 0.01% |
| Ergoteles LLC | 25,485 | $585.4K | 0.02% |
| Duality Advisers, LP | 24,659 | $566.4K | 0.06% |
| Trexquant Investment LP | 24,613 | $565.4K | 0.02% |
| Candriam Luxembourg S.C.A. | 20,160 | $426.2K | 0.00% |
| Simplex Trading, LLC | 14,834 | $340.0K | 0.02% |
| SEI Investments Co | 11,738 | $269.6K | 0.00% |
| Bayesian Capital Management, LP | 10,802 | $248.1K | 0.03% |
| Northcape Wealth Management, LLC | 10,510 | $241.4K | 0.09% |
| Caption Management, LLC | 4,086 | $93.9K | 0.02% |
| Aquatic Capital Management LLC | 1,100 | $25.0K | 0.00% |
| Spire Wealth Management | 230 | $5.28K | 0.00% |
| EverSource Wealth Advisors, LLC | 56 | $1.29K | 0.00% |
Sold out (12)
Institutions that held Agios Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Parkman Healthcare Partners LLC | 50,000 | $1.40M |
| Qube Research & Technologies Ltd | 39,061 | $1.10M |
| Schonfeld Strategic Advisors LLC | 23,700 | $665.5K |
| Jump Financial, LLC | 20,895 | $586.7K |
| Caxton Associates LP | 13,959 | $392.0K |
| Algert Global LLC | 13,852 | $389.0K |
| Raymond James & Associates | 13,350 | $374.9K |
| HBK Sorce Advisory LLC | 73,798 | $331.0K |
| Aigen Investment Management, LP | 9,814 | $275.6K |
| NinePointTwo Capital | 8,717 | $244.0K |
| Norway Savings Bank | 265 | $7.44K |
| Bell Investment Advisors, Inc | 156 | $4.38K |
Not filed for Q1 2023 yet (1)
Institutions that held Agios Pharmaceuticals, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Monarch Partners Asset Management LLC | 58,246 | $1.64M |